Evaluation effect of Viola odorata vaginal suppository on the treatment of vaginal atrophy in post menopausal wome
Phase 3
Recruiting
- Conditions
- Vaginal Atrophy.Postmenopausal atrophic vaginitisN95.2
- Registration Number
- IRCT20220814055687N1
- Lead Sponsor
- Ardabil University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 60
Inclusion Criteria
Women who had natural menopause confirmed by amenorrhea for one year or increased follicle stimulation hormone FSH>40 IU/I
Having at least two symptoms from the descriptive evaluation table of the vaginal mucosa
Women who are sexually active
being married
Women who are literate
Phone number for follow up
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Viola odorata's efficacy in treating postmenopausal vaginal atrophy?
How does Viola odorata vaginal suppository compare to estrogen-based therapies for atrophic vaginitis (N95.2)?
Are there specific biomarkers that predict response to Viola odorata treatment in postmenopausal women with vaginal atrophy?
What are the potential adverse events associated with Viola odorata vaginal suppository and how are they managed?
What are the current drug classes and compounds being developed for postmenopausal atrophic vaginitis compared to IRCT20220814055687N1's approach?